First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial

Authors: Lee, Ki Hyeong ^a, Lee, Jong-Seok ^b, Sugawara, Shunichi ^c, Kang, Jin Hyoung ^d, Kim, Hye Ryun ^e, Inui, Naoki ^f, Hida, Toyoaki ^{g, 1}, Yoshida, Tatsuya ^h, Tanaka, Hiroshi ⁱ, Yang, Cheng-Ta ^j, Inoue, Takako ^k, Nishio, Makoto ^l, Ohe, Yuichiro ^h, Tamura, Tomohide ^m, Yamamoto, Nobuyuki ⁿ, Yu, Chong-Jen ^o, Akamatsu, Hiroaki ⁿ, Takahashi, Shigeru ^p, Nakagawa, Kazuhiko ^{q, ⁎}

Source: In Lung Cancer March 2025 201

J-TAIL-2: A Prospective, Observational Study of Atezolizumab Combined With Carboplatin and Etoposide in Patients With Extensive-Stage SCLC in Japan

Authors: Miyauchi, Eisaku ^a, Nishio, Makoto ^b, Ohashi, Kadoaki ^c, Osoegawa, Atsushi ^d, Kikuchi, Eiki ^e, Kimura, Hideharu ^f, Goto, Yasushi ^g, Shimizu, Junichi ^h, Yoshioka, Hiroshige ⁱ, Yoshino, Ichiro ^j, Misumi, Toshihiro ^k, Katakami, Nobuyuki ^l, Oki, Masahide ^m, Kijima, Takashi ⁿ, Chikamori, Kenichi ^o, Nishino, Kazumi ^p, Kobayashi, Yuki ^q, Miwa, Asako ^q, Tanaka, Misa ^q, Gemma, Akihiko ^{r, ∗}

Source: In JTO Clinical and Research Reports March 2025 6(3)

Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis

Authors: Peters, Solange ^{a, ∗}, Paz-Ares, Luis G. ^b, Reck, Martin ^c, Carbone, David P. ^d, Brahmer, Julie R. ^e, Borghaei, Hossein ^f, Lu, Shun ^g, O’Byrne, Kenneth J. ^h, John, Thomas ⁱ, Ciuleanu, Tudor-Eliade ^j, Schenker, Michael ^k, Bernabe Caro, Reyes ^l, Nishio, Makoto ^m, Cobo, Manuel ⁿ, Lee, Jong-Seok ^o, Zurawski, Bogdan ^p, Pluzanski, Adam ^q, Aoyama, Takekazu ^r, Tschaika, Marina ^s, Devas, Vipul ^t, Grootendorst, Diederik J. ^u, Ramalingam, Suresh S. ^v

Source: In Journal of Thoracic Oncology January 2025 20(1):94-108

Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1–49 %): TOPGAN2023-01

Authors: Tanaka, Hisashi, Makiguchi, Tomonori, Tozuka, Takehiro, Kawashima, Yosuke, Oba, Tomohiro, Tsugitomi, Ryosuke, Koyama, Junji, Tambo, Yuichi, Ogusu, Shinsuke, Saiki, Masafumi, Gyotoku, Hiroshi, Hasegawa, Tsukasa, Miyauchi, Eisaku, Sonoda, Tomoaki, Saito, Ryota, Nakatomi, Katsumi ^°, Sakatani, Toshio, Kudo, Keita, Tsuchiya-Kawano, Yuko, Nishio, Makoto

Source: In European Journal of Cancer December 2024 213

Comprehensive serum biomarker analysis reveals IL-8 changes as the only predictor of the effectiveness of immune checkpoint inhibitors for patients with advanced non-small cell lung cancer

Authors: Akamatsu, Hiroaki, Koh, Yasuhiro, Nishio, Makoto, Goto, Yasushi, Hayashi, Hidetoshi, Miura, Satoru, Tamada, Koji, Kagamu, Hiroshi, Gemma, Akihiko, Yoshino, Ichiro, Misumi, Toshihiro, Mouri, Atsuto, Saito, Ryota, Takase, Naoto, Yanagitani, Noriko, Nokihara, Hiroshi, Seike, Masahiro, Takamura, Kei, Mori, Masahide, Iwasawa, Shunichiro, Nakagawa, Shintaro, Mitsudomi, Tetsuya

Source: In Lung Cancer December 2024 198

MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer

Authors: Wei, Xinzhao, Uchibori, Ken, Kondo, Nobuyuki, Utsumi, Takahiro, Takemoto, Ai, Koike, Sumie, Takagi, Satoshi, Yanagitani, Noriko, Nishio, Makoto, Katayama, Ryohei

Source: In Cancer Letters 1 November 2024 604

Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial

Authors: Wolf, Jürgen ^*, Hochmair, Maximilian, Han, Ji-Youn, Reguart, Noemi, Souquet, Pierre-Jean, Smit, Egbert F, Orlov, Sergey V, Vansteenkiste, Johan, Nishio, Makoto, de Jonge, Maja, Akerley, Wallace, Garon, Edward B, Groen, Harry J M, Tan, Daniel S W, Seto, Takashi, Frampton, Garrett M, Robeva, Anna, Carbini, Mariana, Le Mouhaer, Sylvie, Yovine, Alejandro, Boran, Aislyn, Bossen, Claudia, Yang, Yiqun, Ji, Lexiang, Fairchild, Lauren, Heist, Rebecca S

Source: In The Lancet Oncology October 2024 25(10):1357-1370

Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial

Authors: Solomon, Benjamin J., Dagogo-Jack, Ibiayi, Lee, Se-Hoon, Boyer, Michael J., Ramalingam, Suresh S., Carcereny, Enric, Felip, Enriqueta, Han, Ji-Youn, Hida, Toyoaki, Hughes, Brett G.M., Kim, Sang-We, Nishio, Makoto, Seto, Takashi, Okamoto, Tatsuro, Zhang, Xiaoxi, Martini, Jean-Francois, Wang, Erjian, De Beukelaer, Steven, Bauer, Todd M.

Source: In JTO Clinical and Research Reports July 2024 5(7)

Real-World Pharmacokinetics, Effectiveness, and Safety of Atezolizumab in Patients With Unresectable Advanced or Recurrent NSCLC: An Exploratory Study of J-TAIL

Authors: Yagishita, Shigehiro, Goto, Yasushi, Nishio, Makoto, Akamatsu, Hiroaki, Hayashi, Hidetoshi, Miura, Satoru, Tamada, Koji, Kagamu, Hiroshi, Hamada, Akinobu, Ohuchi, Mayu, Gemma, Akihiko, Yoshino, Ichiro, Misumi, Toshihiro, Hata, Akito, Hara, Satoshi, Kijima, Takashi, Masaki, Fujita, Iwasawa, Shunichiro, Nakagawa, Shintaro, Tatsuno, Masahiro, Mitsudomi, Tetsuya

Source: In JTO Clinical and Research Reports July 2024 5(7)

RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC

Authors: Nakagawa, Kazuhiko ^{a, ∗}, Garon, Edward B. ^b, Seto, Takashi ^c, Nishio, Makoto ^d, Aix, Santiago Ponce ^e, Paz-Ares, Luis ^e, Chiu, Chao-Hua ^f, Park, Keunchil ^{g, 1}, Novello, Silvia ^h, Nadal, Ernest ⁱ, Nishino, Kazumi ^j, Yoh, Kiyotaka ^k, Shih, Jin-Yuan ^l, Chik, Jeannie Y.K. ^m, Moro-Sibilot, Denis ⁿ, Puri, Tarun ^o, Chacko Varughese, Sunoj ^p, Frimodt-Moller, Bente ^q, Visseren-Grul, Carla ^r, Reck, Martin ^s

Source: In Journal of Thoracic Oncology November 2024

RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome

Authors: Nishio, Makoto, Paz-Ares, Luis, Reck, Martin, Nakagawa, Kazuhiko, Garon, Edward B., Popat, Sanjay, Ceccarelli, Matteo, Graham, Hillary T., Visseren-Grul, Carla, Novello, Silvia

Source: Clinical lung cancer. 24(5):415-428

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100193434945.0x000001&indx=1&recIds=ETOCvdc_100193434945.0x000001

First‐line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non‐squamous non‐small cell lung cancer: Updated survival analysis of the ONO‐4538‐52/TASUKI‐52 randomized controlled trial

Authors: Kim, Hye Ryun, Sugawara, Shunichi, Lee, Jong‐Seok, Kang, Jin‐Hyoung, Inui, Naoki, Hida, Toyoaki, Lee, Ki Hyeong, Yoshida, Tatsuya, Tanaka, Hiroshi, Yang, Cheng‐Ta, Nishio, Makoto, Ohe, Yuichiro, Tamura, Tomohide, Yamamoto, Nobuyuki, Yu, Chong‐Jen, Akamatsu, Hiroaki, Takahashi, Shigeru, Nakagawa, Kazuhiko

Source: Cancer medicine. 12(16):17061-17067

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100192714073.0x000001&indx=1&recIds=ETOCvdc_100192714073.0x000001

Real‐world study of next‐generation sequencing diagnostic biomarker testing for patients with lung cancer in Japan

Authors: Takahashi, Toshiaki, Nishio, Makoto, Nishino, Kazumi, Yoshiki, Yasumasa, Shiraiwa, Naoko, Emir, Birol, Iadeluca, Laura, Yatabe, Yasushi, Nishio, Kazuto

Source: Cancer science. 114(6):2524-2533

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100192111164.0x000001&indx=1&recIds=ETOCvdc_100192111164.0x000001

Brigatinib in Japanese patients with ALK‐positive non‐small‐cell lung cancer: Final results of the phase 2 J‐ALTA trial

Authors: Yoshida, Tatsuya, Kumagai, Toru, Toyozawa, Ryo, Katayama, Ryohei, Nishio, Makoto, Seto, Takashi, Goto, Koichi, Yamamoto, Nobuyuki, Ohe, Yuichiro, Kudou, Kentarou, Asato, Takayuki, Zhang, Pingkuan, Nakagawa, Kazuhiko

Source: Cancer science. 114(9):3698-3707

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100191751128.0x000001&indx=1&recIds=ETOCvdc_100191751128.0x000001

Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non‐small‐cell lung cancer in KEYNOTE‐407

Authors: Sugawara, Shunichi, Tanaka, Kentaro, Imamura, Fumio, Yamamoto, Nobuyuki, Nishio, Makoto, Okishio, Kyoichi, Hirashima, Tomonori, Tanaka, Hiroshi, Fukuhara, Tatsuro, Nakahara, Yasuharu, Kurata, Takayasu, Katakami, Nobuyuki, Okada, Morihito, Horinouchi, Hidehito, Udagawa, Hibiki, Kasahara, Kazuo, Satouchi, Miyako, Saka, Hideo, Tokito, Takaaki, Hosomi, Yukio, Aoe, Keisuke, Kishi, Kazuma, Ohashi, Kadoaki, Yokoyama, Takuma, Adachi, Noriaki, Noguchi, Kazuo, Schwarzenberger, Paul, Kato, Terufumi

Source: Cancer science. 114(8):3330-3341

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100189903742.0x000001&indx=1&recIds=ETOCvdc_100189903742.0x000001

Phase 1 study of DS‐1205c combined with gefitinib for EGFR mutation‐positive non‐small cell lung cancer

Authors: Goto, Koichi, Shiraishi, Yoshimasa, Murakami, Haruyasu, Horinouchi, Hidehito, Toyozawa, Ryo, Takeda, Masayuki, Uno, Makiko, Crawford, Nigel, McGill, Joseph, Jimbo, Takeshi, Ishigami, Masato, Takayama, Gensuke, Nakayama, Shintaro, Ohwada, Shoichi, Nishio, Makoto

Source: Cancer medicine. 12(6):7090-7104

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100185281332.0x000001&indx=1&recIds=ETOCvdc_100185281332.0x000001

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227

Authors: Brahmer, Julie R., Lee, Jong-Seok, Ciuleanu, Tudor-Eliade, Bernabe Caro, Reyes, Nishio, Makoto, Urban, Laszlo, Audigier-Valette, Clarisse, Lupinacci, Lorena, Sangha, Randeep, Pluzanski, Adam, Burgers, Jacobus, Mahave, Mauricio, Ahmed, Samreen, Schoenfeld, Adam J., Paz-Ares, Luis G., Reck, Martin, Borghaei, Hossein, O'Byrne, Kenneth J., Gupta, Ravi G., Bushong, Judith, Li, Li, Blum, Steven I., Eccles, Laura J., Ramalingam, Suresh S.

Source: Journal of clinical oncology. 41(6):1200-1212

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100183180176.0x000001&indx=1&recIds=ETOCvdc_100183180176.0x000001

Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first‐line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021‐01)

Authors: Uematsu, Shinya, Kitazono, Satoru, Tanaka, Hisashi, Saito, Ryota, Kawashima, Yosuke, Ohyanagi, Fumiyoshi, Tozuka, Takehiro, Ryosuke, Tsugitomi, Sakatani, Toshio, Horiike, Atsushi, Yoshizawa, Takahiro, Saiki, Masafumi, Tambo, Yuichi, Koyama, Junji, Kanazu, Masaki, Kudo, Keita, Tsuchiya‐Kawano, Yuko, Yanagitani, Noriko, Nishio, Makoto

Source: Thoracic cancer. 14(2):168-176

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100170808582.0x000001&indx=1&recIds=ETOCvdc_100170808582.0x000001

Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1

Authors: Reck, Martin, Ciuleanu, Tudor-Eliade, Lee, Jong-Seok, Schenker, Michael, Zurawski, Bogdan, Kim, Sang-We, Mahave, Mauricio, Alexandru, Aurelia, Peters, Solange, Pluzanski, Adam, Caro, Reyes Bernabe, Linardou, Helena, Burgers, Jacobus A., Nishio, Makoto, Martinez-Marti, Alex, Azuma, Koichi, Axelrod, Rita, Paz-Ares, Luis G., Ramalingam, Suresh S., Borghaei, Hossein, O’Byrne, Kenneth J., Li, Li, Bushong, Judith, Gupta, Ravi G., Grootendorst, Diederik J., Eccles, Laura J., Brahmer, Julie R.

Source: In Journal of Thoracic Oncology August 2023 18(8):1055-1069

Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors

Authors: Ariyasu, Ryo, Kakuto, Sho, Miyadera, Keiki, Akita, Takahiro, Kiritani, Ayu, Tsugitomi, Ryosuke, Amino, Yoshiaki, Uchibori, Ken, Kitazono, Satoru, Yanagitani, Noriko, Nishio, Makoto

Source: In JTO Clinical and Research Reports June 2023 4(6)